GLUCOVANCE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Glucovance, and when can generic versions of Glucovance launch?
Glucovance is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in GLUCOVANCE is glyburide; metformin hydrochloride. There are twenty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the glyburide; metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Glucovance
A generic version of GLUCOVANCE was approved as glyburide; metformin hydrochloride by IMPAX LABS INC on February 18th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GLUCOVANCE?
- What are the global sales for GLUCOVANCE?
- What is Average Wholesale Price for GLUCOVANCE?
Summary for GLUCOVANCE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Clinical Trials: | 7 |
| Patent Applications: | 23 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for GLUCOVANCE |
| What excipients (inactive ingredients) are in GLUCOVANCE? | GLUCOVANCE excipients list |
| DailyMed Link: | GLUCOVANCE at DailyMed |
Recent Clinical Trials for GLUCOVANCE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Texas Tech University Health Sciences Center, El Paso | Early Phase 1 |
| Ortho Biotech Products, L.P. | Phase 4 |
| Brigham and Women's Hospital | Phase 4 |
US Patents and Regulatory Information for GLUCOVANCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | GLUCOVANCE | glyburide; metformin hydrochloride | TABLET;ORAL | 021178-001 | Jul 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | GLUCOVANCE | glyburide; metformin hydrochloride | TABLET;ORAL | 021178-002 | Jul 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | GLUCOVANCE | glyburide; metformin hydrochloride | TABLET;ORAL | 021178-003 | Jul 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GLUCOVANCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | GLUCOVANCE | glyburide; metformin hydrochloride | TABLET;ORAL | 021178-001 | Jul 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | GLUCOVANCE | glyburide; metformin hydrochloride | TABLET;ORAL | 021178-003 | Jul 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | GLUCOVANCE | glyburide; metformin hydrochloride | TABLET;ORAL | 021178-002 | Jul 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for GLUCOVANCE
See the table below for patents covering GLUCOVANCE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 013052 | UNA FORMA DE DOSIS ORAL SOLIDA QUE COMPRENDE UNA COMBINACION DE METFORMIN Y GLIBENCLAMIDA | ⤷ Sign Up |
| African Intellectual Property Organization (OAPI) | 11400 | Solid oral dosage form comprising a combination ofmetformin and glibenclamide. | ⤷ Sign Up |
| New Zealand | 503248 | Solid oral dosage form comprising a combination of metformin and glibenclamide | ⤷ Sign Up |
| China | 1146427 | ⤷ Sign Up | |
| European Patent Office | 0974356 | Comprimés contenant une combinaison de glibenclamide et de metformine (Tablets comprising a combination of metformin and glibenclamide) | ⤷ Sign Up |
| Australia | 753604 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
